Blood Clots Should Be Listed As Rare AstraZeneca Side Effect: European Medicines Agency

European Medicines Agencythat blood clots must be listed as a “very uncommon” aspect impact

The Hague, Netherlands:

The European Medicines Company stated Wednesday that blood clots must be listed as a “very uncommon” aspect impact of the AstraZeneca coronavirus vaccine however that the jab’s advantages proceed to outweigh the dangers.

“EMA’s security committee has concluded at present that uncommon blood clots with low blood platelets must be listed as very uncommon negative effects” of the shot, the Amsterdam-based EU drug regulator stated in a press release.

(Apart from the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)